Q2 EPS Forecast for Eli Lilly and Company Lifted by Analyst

Eli Lilly and Company (NYSE:LLY - Free Report) - Investment analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of Eli Lilly and Company in a report issued on Thursday, May 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings of $5.53 per share for the quarter, up from their prior forecast of $5.48. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q3 2025 earnings at $6.30 EPS, Q4 2025 earnings at $6.97 EPS, FY2025 earnings at $22.14 EPS, Q1 2026 earnings at $6.23 EPS, Q2 2026 earnings at $7.21 EPS, Q4 2026 earnings at $9.04 EPS and FY2026 earnings at $30.78 EPS.

LLY has been the subject of several other reports. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Trading Down 0.2%

Shares of NYSE:LLY traded down $1.21 during mid-day trading on Monday, hitting $713.99. The company had a trading volume of 2,631,160 shares, compared to its average volume of 3,622,393. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a fifty day moving average price of $789.29 and a 200 day moving average price of $803.22. The company has a market capitalization of $676.67 billion, a PE ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.58 earnings per share.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the stock. Grassi Investment Management increased its stake in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Grassi Investment Management now owns 79,512 shares of the company's stock worth $61,383,000 after purchasing an additional 225 shares during the last quarter. Elevate Capital Advisors LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at $262,000. Capital & Planning LLC increased its position in Eli Lilly and Company by 15.6% in the fourth quarter. Capital & Planning LLC now owns 481 shares of the company's stock worth $371,000 after buying an additional 65 shares during the last quarter. Garner Asset Management Corp raised its stake in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after buying an additional 12 shares during the period. Finally, Beacon Investment Advisory Services Inc. lifted its position in shares of Eli Lilly and Company by 41.0% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 28,122 shares of the company's stock valued at $21,710,000 after buying an additional 8,172 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.